High analytical concordance between a novel companion diagnostic assay and an IUO assay for BRAF V600E/V600K detection in melanoma

被引：0
|
作者：
O'Donnell, L. [1 ]
Sweet, W. [1 ]
Lu, X. [1 ]
Meynier, F. [2 ]
Derome, A. [3 ]
Ganee, L. [4 ]
Poyet-Gelas, F. [3 ]
Martin, A. [5 ]
Casey, M. [6 ]
Kertesz, N. [7 ]
机构：
[1] BioMerieux Inc, Clin Affairs, Durham, NC USA
[2] BioMerieux Inc, BioMath, Grenoble, France
[3] BioMerieux Inc, V&V, Grenoble, France
[4] BioMerieux Inc, Prod Design & Dev, Grenoble, France
[5] GSK, Oncol, Collegeville, PA USA
[6] GSK, Stat, Collegeville, PA USA
[7] Response Genet Inc, Pharmaceut Liaison Manager, Los Angeles, CA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MC13-0053
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [1] High precision of a novel companion diagnostic assay for the detection of BRAF V600E/V600K in formalin-fixed paraffin-embedded melanoma samples
    O'Donnell, L.
    Sweet, W.
    Lu, X.
    Meynier, F.
    Derome, A.
    Ganee, L.
    Poyet-Gelas, F.
    Martin, A.
    Casey, M.
    Kertesz, N.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S27 - S27
  • [2] BRAF V600E and V600K in Melanoma: Clinicopathologic Correlation
    Purgina, B. M.
    Jelic, T.
    Chiosea, S. I.
    LABORATORY INVESTIGATION, 2012, 92 : 131A - 131A
  • [3] BRAF V600E and V600K in Melanoma: Clinicopathologic Correlation
    Purgina, B. M.
    Jelic, T.
    Chiosea, S. I.
    MODERN PATHOLOGY, 2012, 25 : 131A - 131A
  • [4] A novel companion diagnostic assay for BRAF V600E/K detection in melanoma: High clinical concordance of patient outcomes for trametinib and debrafenib treatment
    O'Donnell, L.
    Sweet, W.
    Lu, X.
    Meynier, F.
    Derome, A.
    Ganee, L.
    Poyet-Gelas, F.
    Martin, A.
    Casey, M.
    Kertesz, N.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S862 - S862
  • [5] Management of V600E and V600K BRAF-Mutant Melanoma
    Haugh, Alexandra M.
    Johnson, Douglas B.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (11)
  • [6] Management of V600E and V600K BRAF-Mutant Melanoma
    Alexandra M. Haugh
    Douglas B. Johnson
    Current Treatment Options in Oncology, 2019, 20
  • [7] The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma
    Amaral, Teresa
    Nouri, Noura
    Garbe, Claus
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (07) : 705 - 715
  • [8] Validation of Idylla BRAF Mutation Assay for the Detection of V600E/D and V600K/R/M Mutations in Patients with Advanced Melanoma
    Collie, J.
    Martelli, A.
    Sabato-Charreun, M.
    Abou Shaar, R.
    Lynch, J.
    Turner, S.
    Barrie, E.
    Ferreira-Gonzalez, A.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2023, 25 (11): : S128 - S129
  • [9] Accuracy evaluation of a novel companion diagnostic method for BRAF V600E/V600K identification in GSK clinical trials
    O'Donnell, L.
    Sweet, W.
    Lu, X.
    Meynier, F.
    Derome, A.
    Ganee, L.
    Poyet-Gelas, F.
    Martin, A.
    Casey, M.
    Kertesz, N.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S26 - S27
  • [10] Putative genomic characteristics of BRAF V600K versus V600E cutaneous melanoma
    Li, Yuanyuan
    Umbach, David M.
    Li, Leping
    MELANOMA RESEARCH, 2017, 27 (06) : 527 - 535
12345